Global study digs into immunotherapy success in kidney cancer
NCT ID NCT05287464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gathers information from over 1,200 people worldwide who have metastatic kidney cancer and received immunotherapy as their first treatment. Researchers will look at how long patients live, how well tumors shrink, and what genetic or immune factors might predict better outcomes. The goal is to learn from real-world experiences to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA ( MRCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ospedale di Macerata, UOC Oncologia
RECRUITINGProvince of Macerata, Macerata, 62100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Kidney cancer drug studied in Real-World patients
- Timing is everything: new trial tests surgery before or after immunotherapy for kidney cancer
- Triple attack on kidney cancer: immune booster, radiation, and immunotherapy
- New hope for advanced kidney cancer: experimental drug enters human trials
- Could a PET scan let kidney cancer patients pause treatment?
- New hope for kidney cancer: triple-drug combo enters phase 2 trial